TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00607243

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: smallpox vaccine CJ-50300
Description: Conventional dose group: 2.5 x 10 5 pfu/dose Diluted dose group:2.5 x 10 4 pfu/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: smallpox vaccine CJ-50300
Description: Conventional dose group: 2.5 x 10 5 pfu/dose Diluted dose group:2.5 x 10 4 pfu/dose
Study: NCT03803839

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT01843790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCS-100
Description: The amount (in mg) of GCS-100 to be administered will be determined based on body surface area, which will be calculated based on body weight and height. The study drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP. Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCS-100
Description: The amount (in mg) of GCS-100 to be administered will be determined based on body surface area, which will be calculated based on body weight and height. The study drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP. Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Saline
Description: The amount (in mg) of drug to be administered will be determined based on body surface area, which will be calculated based on body weight and height. The drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP. Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
Study: NCT03291288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolbutamide
Description: Commercially available tolbutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Commercially available midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Description: Pexidartinib is formulated as opaque, white, 200-mg capsules
Study: NCT02962427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion Block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural blood patch
Study: NCT00449839

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin Aspart
Description: A; CSII without bolus: 8 hours of constant insulin infusion. B; CSII with bolus: 8 hours of a constant insulin infusion starting with a s.c. bolus.~C; CSII with bolus, optional: 8 hours of a constant insulin infusion starting with a different bolus than period B. This period is optional and it will be evaluated after period A and B if period C is conducted.
Study: NCT02586571

Intervention type: BEHAVIORAL
Intervention: Breastfeeding
Description: Breastfeeding at 5.5 months of age (exclusive or partial)

Intervention type: BEHAVIORAL
Intervention: Breastfeeding
Description: Breastfeeding at 5.5 months of age (exclusive or partial)

Intervention type: BEHAVIORAL
Intervention: Breastfeeding
Description: Breastfeeding at 5.5 months of age (exclusive or partial)
Study: NCT00727701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aftercare summary
Description: A personalized, targeted set of self-care instructions for venous ulcer prevention, including a graphical depiction of patient adherence to self-care goals.
Study: NCT01276379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI (m)
Description: FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:~* Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.~* l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.~* One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.~* 5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX-6 (m)
Description: FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:~* Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.~* l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.~* One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.~* 5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: - 500 mg/m2 i.v. Every 2 weeks.
Study: NCT03887949

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group VCV
Description: Volume controlled ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group PCV
Description: Pressure controlled ventilation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group PCV-VG
Description: Pressure controlled ventilation with volume guarantee
Study: NCT02955732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: A 2-4 µg/kg dose of the study drug, 2 µg/kg of intranasal dexmedetomidine, will be administered using a LMA MAD Nasal™ -device approximately 20 min prior to planned sedation/anesthesia.
Study: NCT04648722

Intervention type: PROCEDURE
Intervention: Hemithyroidectomy
Description: We investigated patients who received a hemithyroidectomy at the Department of General Surgery, Division of Endocrine Surgery and a follow-up visit (3-12 months post-surgery) at the thyroid outpatient clinic of the Department of Endocrinology and Metabolism, Medical University of Vienna between 1994 and 2018.

Intervention type: PROCEDURE
Intervention: Hemithyroidectomy
Description: We investigated patients who received a hemithyroidectomy at the Department of General Surgery, Division of Endocrine Surgery and a follow-up visit (3-12 months post-surgery) at the thyroid outpatient clinic of the Department of Endocrinology and Metabolism, Medical University of Vienna between 1994 and 2018.
Study: NCT01657786

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: administration of ondanstron and screening of genomic DNA
Description: Thirty minutes before the end of surgery, ondansetron 0.1 mg/kg is administered intravenously. We assess an episode of PONV at first 2 h and 2-24 h after surgery. Genomic DNA was prepared and screened. The incidence of PONV is compared among genotypes in 5-HT3 receptor gene polymorphisms (5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG).
Study: NCT02497248

Intervention type: PROCEDURE
Intervention: Pulmonary vein ablation
Description: Simultaneous biatrial endocardial electroanatomical mapping by high-density basket catheter (64 pin) and customized body surface mapping (57 electrodes) followed by circumferential pulmonary vein ablation.

Intervention type: PROCEDURE
Intervention: Pulmonary vein ablation
Description: Simultaneous biatrial endocardial electroanatomical mapping by high-density basket catheter (64 pin) and customized body surface mapping (57 electrodes) followed by circumferential pulmonary vein ablation.

Intervention type: PROCEDURE
Intervention: Pulmonary vein ablation
Description: Simultaneous biatrial endocardial electroanatomical mapping by high-density basket catheter (64 pin) and customized body surface mapping (57 electrodes) followed by circumferential pulmonary vein ablation.
Study: NCT00488332

Intervention type: PROCEDURE
Intervention: Optical Coherence Tomography
Description: Before radiation treatment and once a week thereafter.

Intervention type: PROCEDURE
Intervention: Fluorescence Spectroscopy
Description: Before radiation treatment and once a week thereafter.

Intervention type: BEHAVIORAL
Intervention: Pain Scale Questionnaire
Description: Administered before the examination, OCT, and FS and immediately afterward.
Study: NCT03590366

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: B244
Description: B244 Suspension
Study: NCT00449839

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin Aspart
Description: A; CSII without bolus: 8 hours of constant insulin infusion. B; CSII with bolus: 8 hours of a constant insulin infusion starting with a s.c. bolus.~C; CSII with bolus, optional: 8 hours of a constant insulin infusion starting with a different bolus than period B. This period is optional and it will be evaluated after period A and B if period C is conducted.

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin Aspart
Description: A; CSII without bolus: 8 hours of constant insulin infusion. B; CSII with bolus: 8 hours of a constant insulin infusion starting with a s.c. bolus.~C; CSII with bolus, optional: 8 hours of a constant insulin infusion starting with a different bolus than period B. This period is optional and it will be evaluated after period A and B if period C is conducted.
Study: NCT02766647

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim Hospira (US)
Description: 5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection
Study: NCT03590366

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle suspension
Study: NCT02958631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Study: NCT00721149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Description: The Biosense Webster® NAVISTAR THERMOCOOL Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.
Study: NCT04449120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet-based culinary intervention
Description: The culinary intervention was developed integrating four culinary workshops that were given every week, once per week, during one-month intervention. The duration of each culinary workshop was 3,5 h, thus, the program provided a total of 14h of practice in cooking activities. The courses took place in a well-equipped kitchen from the Basque Culinary Center. Each culinary workshop was divided in two differentiated parts in order to work on the specific objectives established for each day. All cooking classes began with a theoretical introductory part that aimed to explain the main take-home messages from the workshop. Subsequently, every class was characterized by a hands-on part that included the demonstration and practical preparation of different elaborations based on the use specific cooking techniques and healthy ingredients. At the end of the session, participants were encouraged to taste the prepared meals, to share their preferences and their view about the cooking experience.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet-based nutritional education intervention
Description: The patients in the nutritional intervention group will receive dietary advice on how to follow a Mediterranean diet. The dietary recommendations will be given at the beginning of the study by nutritionists using comprehensive written material.
Study: NCT03806101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: 200 mg dose of PF-04965842 once daily (QD) for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: 200 mg dose of PF-04965842 once daily (QD) for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Single 10 mg dose of rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Single 10 mg dose of rosuvastatin
Study: NCT04064073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: Tablets, Oral, once daily single dose
Study: NCT02766647

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim Hospira (US)
Description: 5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: US-approved Neupogen®
Description: 5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: US-approved Neupogen®
Description: 5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection
Study: NCT02184819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levosimendan
Description: 24 hour continuous infusion at the rate of 0,1 µg/kg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 hour infusion at a rate of 0,1 µg/kg/min assuming that it contains study drug
Study: NCT00161213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study: NCT04149340

Intervention type: DRUG
Group type: OTHER
Intervention: Cataract surgery
Description: Patient's satisfaction and surgeon's satisfaction was assessed by four Lickert's scales, ranging from one to four. hemodynamic parameters before incision, 10 min post-incision and at the end of the surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cataract surgery
Description: Patient's satisfaction and surgeon's satisfaction was assessed by four Lickert's scales, ranging from one to four. hemodynamic parameters before incision, 10 min post-incision and at the end of the surgery

Intervention type: DRUG
Group type: OTHER
Intervention: Cataract surgery
Description: Patient's satisfaction and surgeon's satisfaction was assessed by four Lickert's scales, ranging from one to four. hemodynamic parameters before incision, 10 min post-incision and at the end of the surgery
Study: NCT05402709

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Posterior mobilisation technique
Description: Posterior mobilisation technique were applied

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Posterior capsule stretching
Description: Posterior capsule stretching were applied
Study: NCT01009593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869
Description: Tablets, Oral, 17.5 mg, Once Daily, Until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Tablets, Oral, 400 mg, Twice Daily, Until disease progression or unacceptable toxicity.
Study: NCT02198534

Intervention type: DEVICE
Intervention: Methodology of visual acuity assessment
Study: NCT01506856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel(intravenous) + Carboplatin(intravenous)
Description: Paclitaxel(intravenous) + Carboplatin(intravenous) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IV infusion, Day1 A total of 6 to 8 cycles will be repeated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel(intravenous) + Carboplatin(intraperitoneal)
Description: Paclitaxel(intravenous) + Carboplatin(intraperitoneal) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IP injection, Day1 A total of 6 to 8 cycles will be repeated.
Study: NCT01266616

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Profectus HIV MAG pDNA vaccine
Description: 3,000 mcg admixture of two vaccine plasmids: ProfectusVax DNA Plasmid (HIV-1 gag/pol) and ProfectusVax DNA Plasmid (HIV-1 nef/tat/vif, env) at Weeks 0, 4, and 12

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Profectus HIV MAG pDNA vaccine
Description: 3,000 mcg admixture of two vaccine plasmids: ProfectusVax DNA Plasmid (HIV-1 gag/pol) and ProfectusVax DNA Plasmid (HIV-1 nef/tat/vif, env) at Weeks 0, 4, and 12

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Profectus HIV MAG pDNA vaccine
Description: 3,000 mcg admixture of two vaccine plasmids: ProfectusVax DNA Plasmid (HIV-1 gag/pol) and ProfectusVax DNA Plasmid (HIV-1 nef/tat/vif, env) at Weeks 0, 4, and 12

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Profectus HIV MAG pDNA vaccine
Description: 3,000 mcg admixture of two vaccine plasmids: ProfectusVax DNA Plasmid (HIV-1 gag/pol) and ProfectusVax DNA Plasmid (HIV-1 nef/tat/vif, env) at Weeks 0, 4, and 12

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Profectus HIV MAG pDNA vaccine
Description: 3,000 mcg admixture of two vaccine plasmids: ProfectusVax DNA Plasmid (HIV-1 gag/pol) and ProfectusVax DNA Plasmid (HIV-1 nef/tat/vif, env) at Weeks 0, 4, and 12

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12
Description: Administered at Weeks 0, 4, and 12

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12
Description: Administered at Weeks 0, 4, and 12

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12
Description: Administered at Weeks 0, 4, and 12

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12
Description: Administered at Weeks 0, 4, and 12

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injections at Weeks 0, 4, and 12

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injections at Weeks 0, 4, and 12

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injections at Weeks 0, 4, and 12

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injections at Weeks 0, 4, and 12

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injections at Weeks 0, 4, and 12
Study: NCT00801944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral
Study: NCT04273815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-A3334
Description: TQ-A3334 is a highly efficient and highly selective TLR-7 agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including IFN-α (interferon-α), IL-12 (Interleukin 12), TNF-α, and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-A3334
Description: TQ-A3334 is a highly efficient and highly selective TLR-7 agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including IFN-α (interferon-α), IL-12 (Interleukin 12), TNF-α, and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib is a multi-target receptor tyrosine kinase inhibitor.
Study: NCT03477162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be given to patients prior to surgery.
Study: NCT03628443

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroblast Growth Factor 23
Description: A sample of blood is tested for levels of fibroblast growth factor 23

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroblast Growth Factor 23
Description: A sample of blood is tested for levels of fibroblast growth factor 23
Study: NCT00226252

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Instruction Only
Description: Video details an individual propelling a manual wheelchair with biomechanically correct propulsion technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Instruction and Feedback
Description: Individuals will watch video of correct propulsion technique and will receive real-time feedback from the SMART Wheel as they push their wheelchair to help optimize their propulsion technique.
Study: NCT04135547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intra-osseous access vs. intra-venous access
Description: EZ-IO®: The Arrow® Intraosseous Vascular Access System from Teleflex IV-catheter: form local qualified manufactures

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intra-osseous access vs. intra-venous access
Description: EZ-IO®: The Arrow® Intraosseous Vascular Access System from Teleflex IV-catheter: form local qualified manufactures
Study: NCT04064073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin IR
Description: Metformin IR 1000mg, Tablets, Oral, BID for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001+Metformin IR
Description: Tablets, Oral, once daily single dose DWP16001 Metformin IR 1000mg
Study: NCT00719147

Intervention type: PROCEDURE
Intervention: MRI
Description: Not performed for study purposes, MRI will be done as part of routine clinical visit. Findings will be used for study.

Intervention type: OTHER
Intervention: Functional Status and Symptom Questionnaire
Description: Questionnaire
Study: NCT00169377

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: deep brain stimulation
Description: Stimulator on followed by off

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: deep brain stimulation
Description: Stimulator on followed by off

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No stimulation
Description: Stimulator off followed by on

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No stimulation
Description: Stimulator off followed by on
Study: NCT03693885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxytocin challenge test (OCT)
Description: Infusion of oxytocin 5 IU/500 ml Ringer® lactate at a rate of 12 ml/h and doubled every 10 min until three uterine contractions per 10-min interval are induced, at which point it will be stopped.
Study: NCT02656329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iobenguane I -123 Injection
Description: Iobenguane I-123 Injection, AdreView. All participants scheduled for an Iobenguane I-123 Injection, AdreView scan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator
Description: In the Iobenguane I-123 Injection group, participants with H/M ratio less or equal to 1.6 underwent ICD device implantation, while those with H/M ratio greater than or equal to 1.6 did not undergo ICD implantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thyroid blocking
Description: Participants received a thyroid blocking agent before the Iobenguane I-123 Injection, AdreView, scan unless medically not indicated, according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iobenguane I -123 Injection
Description: Iobenguane I-123 Injection, AdreView. All participants scheduled for an Iobenguane I-123 Injection, AdreView scan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator
Description: All participants allocated to the SoC (control) group underwent ICD implantation.